MétaCan
Menu
Back to cohort
Record W4413684499 · doi:10.51731/cjht.2025.1204

Ruxolitinib (Opzelura)

2025· article· en· W4413684499 on OpenAlexaboutno aff
CDA-AMC

Bibliographic record

VenueCanadian Journal of Health Technologies · 2025
Typearticle
Languageen
FieldMedicine
TopicMyeloproliferative Neoplasms: Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsRuxolitinibComputer scienceMedicineInternal medicineMyelofibrosisBone marrow

Abstract

fetched live from OpenAlex

Canada’s Drug Agency (CDA-AMC) recommends that Opzelura not be reimbursed by public drug plans for topical treatment of nonsegmental vitiligo in adult and pediatric patients aged 12 years and older. Evidence from 2 clinical trials demonstrated that about 30% of patients using Opzelura saw significant improvement in facial repigmentation, compared to around 8% to 11% using a placebo. More patients also reported that their vitiligo became less noticeable or no longer noticeable than those who received placebo. However, the impact of vitiligo on daily life varies, and the treatment did not lead to meaningful improvements in overall health-related quality of life (HRQoL). The studies only compared Opzelura to a placebo; therefore, there is no data on how it performs against other commonly used treatments. The Canadian Drug Expert Committee (CDEC) recognized that vitiligo can seriously affect people’s lives, especially those with darker skin tones, who may face stigma, loss of identity, and low self-esteem. Most trial participants had lighter skin tones, and the treatment did not improve their HRQoL. These limitations make it difficult to know how effective Opzelura would be for those most affected by vitiligo.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Other · Consensus signal: none
Teacher disagreement score0.011
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0080.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.022
GPT teacher head0.321
Teacher spread0.299 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreOther

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueCanadian Journal of Health TechnologiesSame topicMyeloproliferative Neoplasms: Diagnosis and TreatmentFrench-language works237,207